Hence, these findings suggest that assessment of baseline MMP-3 and other biomarkers of joint destruction, in conjunction with existing serological markers and clinical measures, may provide additional long-term prognostic information for patients with RA. Here, MMP3 is linked to rheumatoid arthritis.